IX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc (NASDAQ: SEEL). Seelos will have exclusive worldwide rights for Wafermine, except China, including Hong Kong, Macau, and Taiwan - for which iX Biopharma will retain the rights. Seelos will also have...
Gov. Michelle Lujan Grisham and the New Mexico Department of Agriculture (NMDA) announced Nov. 17 that the state’s Chile Labor Incentive Program (CLIP) has been extended to the end of January 2022 to cover the New Mexico red chile pepper harvest. Lujan Grisham announced in August that the state was...
Clustering of synapses allows neurons to overcome attenuation of electrical signals at dendrites. However, we show in avian binaural coincidence detectors computing interaural time difference for sound localization that clustering of synapses rather promotes the dendritic attenuation but augments the intensity tolerance of the binaural computations. Using glutamate uncaging, we found in the neurons that synapses were clustered at distal dendritic branches. Modeling revealed that this strengthened sublinear integration within a dendritic tree but enabled the integration of signals from different trees when inputs grow stronger, preventing monoaural output and maintaining the dynamic range of binaural computation. The extent of this clustering differed according to dendritic length and frequency tuning of neurons, being most prominent for long dendrites and low-frequency tuning. This ensures binaural spatial hearing for wide intensity and frequency ranges, highlighting the importance of coupling of synapse geometry with dendritic morphology and input frequency in sensory signal processing.
Schizophrenia is a polygenetic disorder whose clinical onset is often associated with behavioral stress. Here, we present a model of disease pathogenesis that builds on our observation that the synaptic immediate early gene NPTX2 is reduced in cerebrospinal fluid of individuals with recent onset schizophrenia. NPTX2 plays an essential role in maintaining excitatory homeostasis by adaptively enhancing circuit inhibition. NPTX2 function requires activity-dependent exocytosis and dynamic shedding at synapses and is coupled to circadian behavior. Behavior-linked NPTX2 trafficking is abolished by mutations that disrupt select activity-dependent plasticity mechanisms of excitatory neurons. Modeling NPTX2 loss of function results in failure of parvalbumin interneurons in their adaptive contribution to behavioral stress, and animals exhibit multiple neuropsychiatric domains. Because the genetics of schizophrenia encompasses diverse proteins that contribute to excitatory synapse plasticity, the identified vulnerability of NPTX2 function can provide a framework for assessing the impact of genetics and the intersection with stress.
This week the stock market of Pasithea Therapeutics illustrates a positive sign. On Monday, the worth of the corporation is sharply soared to $8.16, resulting in a 153% profit. Even now in the pre-market trading session is surging by 17% on a volume of 189,781,444. Such a rapid improvement in prices occurred after the declaring that its subsidiary Pasithea Clinics has been approved to provide esketamine nasal spray. In short, the nasal spray is for treating depression in adults and has begun offering the treatment in its Knightsbridge, London location. However, it says that treatment is only available at three clinics in the United Kingdom.
Pasithea Therapeutics Corp's (NASDAQ: KTTA) wholly-owned subsidiary, Pasithea Clinics, has been approved to provide esketamine nasal spray (Spravato) for treatment-resistant depression (TRD) in adults. The Company has begun offering the treatment in its Knightsbridge, London location. Pasithea Clinics is one of only three accredited clinics in the U.K. approved to...
The Power Play by The Market Herald Releases New Interviews with Algernon Pharmaceuticals, Better Plant Sciences, and Mednow Inc. Discussing Their Latest News
VANCOUVER, BC / ACCESSWIRE / November 24, 2021 / The Power Play by The Market Herald releases new interviews with Algernon Pharmaceuticals, Better Plant Sciences and Mednow Inc. discussing their latest news. The Power Play by The Market Herald provides investors with a quick snapshot of what they need to...
Astrocytes modulate extracellular neurotransmitter levels and excitatory neurotransmission in dorsolateral striatum via dopamine D2 receptor signaling
Astrocytes provide structural and metabolic support of neuronal tissue, but may also be involved in shaping synaptic output. To further define the role of striatal astrocytes in modulating neurotransmission we performed in vivo microdialysis and ex vivo slice electrophysiology combined with metabolic, chemogenetic, and pharmacological approaches. Microdialysis recordings revealed that intrastriatal perfusion of the metabolic uncoupler fluorocitrate (FC) produced a robust increase in extracellular glutamate levels, with a parallel and progressive decline in glutamine. In addition, FC significantly increased the microdialysate concentrations of dopamine and taurine, but did not modulate the extracellular levels of glycine or serine. Despite the increase in glutamate levels, ex vivo electrophysiology demonstrated a reduced excitability of striatal neurons in response to FC. The decrease in evoked potentials was accompanied by an increased paired pulse ratio, and a reduced frequency of spontaneous excitatory postsynaptic currents, suggesting that FC depresses striatal output by reducing the probability of transmitter release. The effect by FC was mimicked by chemogenetic inhibition of astrocytes using Gi-coupled designer receptors exclusively activated by designer drugs (DREADDs) targeting GFAP, and by the glial glutamate transporter inhibitor TFB-TBOA. Both FC- and TFB-TBOA-mediated synaptic depression were inhibited in brain slices pre-treated with the dopamine D2 receptor antagonist sulpiride, but insensitive to agents acting on presynaptic glutamatergic autoreceptors, NMDA receptors, gap junction coupling, cannabinoid 1 receptors, Âµ-opioid receptors, P2 receptors or GABAA receptors. In conclusion, our data collectively support a role for astrocytes in modulating striatal neurotransmission and suggest that reduced transmission after astrocytic inhibition involves dopamine.
Algernon Pharmaceuticals Announces Positive Feedback From U.S. FDA For Phase 1 Ifenprodil Small Cell Lung Cancer Study
VANCOUVER, British Columbia, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has received positive feedback from the U.S. Food and Drug Administration (U.S. FDA) at its pre-IND (Investigational New Drug) meeting for its investigation of NP-120 (Ifenprodil) for the treatment of small cell lung cancer (SCLC). Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B).